Abstract: Chemical agents, such as derivatives of hydroxypiperidine moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Abstract: Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.

Abstract: Chemical agents, such as derivatives of hydroxypiperidine moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Abstract: Methods for identifying compounds having similar biological activity based on similarity in genetic expression profile in cells contacted with one or more of said compounds, along with specifically identified compounds, are disclosed.

Abstract: A method for producing a DNA microarray for biological assays comprising a plurality of biosites located on a solid substrate. Each biosite having at least one set of networked oligonucleotides of medium to long lengths attached to the substrate by predominantly non-covalent means. The oligonucleotide strands are chemically presynthesized, exhibit no predetermined spatial orientation on the substrate surface, and have three-dimensional freedom of movement when in a hybridization solution. The oligonucleotides are chemically unmodified having a length of about 30 bases or longer. Preferably, the oligonucleotides are from about 45 bases to 85 bases, but some embodiments may include very long oligonucleotides of over 100 bases.